Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies

European Journal of Cancer

Volumn 44, Issue 15, 2008, Pages 2152-2161

  Chowdhury, Simon ^a   Larkin, James M G ^b   Gore, Martin E ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Bevacizumab; Everolimus; Kinase inhibitor; Metastatic renal carcinoma; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; ERLOTINIB; EVEROLIMUS; GEFITINIB; INTERFERON; LAPATINIB; PAZOPANIB; PLACEBO; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; KIDNEY METASTASIS; METASTASIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RASH; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; SIROLIMUS;

EID: 53049093277     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.06.028     Document Type: Article

References (74)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
2. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 8 (1999) 2530-2540
3. Beck S.D., Patel M.I., Snyder M.E., et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 11 1 (2004) 71-77
4. Cheville J.C., Lohse C.M., Zincke H., Weaver A.L., and Blute M.L. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27 5 (2003) 612-624
5. Yagoda A., and Bander N.H. Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 44 6 (1989) 338-345
6. Harris D.T. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol 10 4 (1983) 422-430
7. Horoszewicz J.S., and Murphy G.P. An assessment of the current use of human interferons in therapy of urological cancers. J Urol 142 5 (1989) 1173-1180
8. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical research council renal cancer collaborators. Lancet 1999;353(9146):14-7.
9. Pyrhonen S., Salminen E., Ruutu M., et al. Prospective randomised trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17 9 (1999) 2859-2867
10. Rosenberg S.A., Yang J.C., White D.E., and Steinberg S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228 3 (1998) 307-319
11. Yao M., Yoshida M., Kishida T., et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 94 20 (2002) 1569-1575
12. Kim W.Y., and Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 22 24 (2004) 4991-5004
13. Ohh M., Park C.W., Ivan M., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2 7 (2000) 423-427
14. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 103 2 (2000) 211-225
15. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 1 (2003) 327-337
16. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 9 (2003) 3597-3605
17. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 1 (2006) 25-35
18. O'Farrell A.M., Foran J.M., Fiedler W., et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9 15 (2003) 5465-5476
19. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 1 (2006) 16-24
20. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 21 (2006) 2516-2524
21. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med 356 2 (2007) 115-124
22. Srinivas S., Roigas J., Gillessen S., et al. Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): updated results. J Clin Oncol 25 18S (2007) 5040
23. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 19 (2004) 7099-7109
24. Sridhar S.S., Hedley D., and Siu L.L. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4 4 (2005) 677-685
25. Awada A., Hendlisz A., Gil T., et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Brit J Cancer 92 10 (2005) 1855-1861
26. Moore M., Hirte H.W., Siu L., et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16 10 (2005) 1688-1694
27. Strumberg D., Richly H., Hilger R.A., et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 5 (2005) 965-972
28. Strumberg D., Voliotis D., Moeller J.G., et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 40 12 (2002) 580-581
29. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomised discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 16 (2006) 2505-2512
30. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 356 2 (2007) 125-134
31. Szczylik C., Demkow T., Staehler M., et al. Randomised phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 25 18S (2007) 5025
32. Amato R., Harris J.P., Dalton M., et al. A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 25 18S (2007) 5026
33. Ryan C.W., Goldman B.H., Lara Jr. P.N., et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 25 22 (2007) 3296-3301
34. Gollob J.A., Rathmell W.K., Richmond T.M., et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 25 22 (2007) 3288-3295
35. Rugo H.S., Herbst R.S., Liu G., et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23 24 (2005) 5474-5783
36. Rixe O., Bukowski R.M., Michaelson M.D., et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8 11 (2007) 975-984
37. Rini B., Wilding G.T., Hudes G., et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol 25 18S (2007) 5032
38. Sonpavde G., and Hutson T.E. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 9 2 (2007) 115-119
39. Hutson T., Davis I.D., Machiels J.P., et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomised discontinuation trial (RDT). J Clin Oncol 25 18S (2007) 5031
40. Hudson C.C., Liu M., Chiang G.G., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22 20 (2002) 7004-7014
41. Hara S., Oya M., and Mizuno R. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 16 6 (2005) 928-933
42. Shin Lee J., Seok Kim H., Bok Kim Y., Cheol Lee M., and Soo Park C. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J Surg Oncol 84 3 (2003) 166-172
43. Vignot S., Faivre S., Aguirre D., and Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16 4 (2005) 525-537
44. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomised phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 5 (2004) 909-918
45. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl J Med 356 22 (2007) 2271-2281
46. Negrier S., Perol D., Ravaud A., et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomised controlled trial. Cancer 110 11 (2007) 2468-2477
47. Jac J., Giessinger S., Khan M., Willis J., Chiang S., and Amato R. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 25 18S (2007) 5107
48. Motzer R., Escudier B., Oudard S., et al. RAD001 versus placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized double-blind, multicenter phase-III study. J Clin Oncol 26 (2008) 87
49. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3 5 (2004) 391-400
50. Yang J.C., Haworth L., Sherry R.M., et al. A randomised trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New Engl J Med 349 5 (2003) 427-434
51. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 9605 (2007) 2103-2111
52. Rini BI, Halabi S, Rosenberg JE, et al. Small EJ. CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. In: 2008 ASCO genitourinary cancers symposium [Abstract 350].
53. Uhlman D.L., Nguyen P., Manivel J.C., et al. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin Cancer Res 1 8 (1995) 913-920
54. Dawson N.A., Guo C., Zak R., et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 10 23 (2004) 7812-7819
55. Hainsworth J.D., Sosman J.A., and Spigel D.R. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23 31 (2005) 7889-7896
56. Bukowski R.M., Kabbinavar F.F., Figlin R.A., et al. Randomised phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25 29 (2007) 4536-4541
57. Ravaud A., Gardner J., Hawkins R., et al. Tykerb renal cell cancer study group and GSK CoreT efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 24 18S (2006) 4502
58. Rini B.I., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99 1 (2007) 81-83
59. Tamaskar I., Bukowski R., Elson P., et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19 2 (2008) 265-268
60. Atkins M., Regan M., McDermott D., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11 10 (2005) 3714-3721
61. Choueiri T.K., Plantade A., Elson P., et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26 1 (2008) 127-131
62. Dutcher J, de Souza P, Figlin R, et al. Effect of temsirolimus versus interferon-α on survival of patients with advanced renal cell carcinoma of different tumor histologies. In: 2008 ASCO genitourinary cancers symposium. Abstract 384.
63. Eder J., Heath E., Appleman L., et al. Phase I experience with c-MET inhibitor XL880 administered orally to patients (pts) with solid tumors. J Clin Oncol 25 18S (2007) 3526
64. Ross R.W., Stein M., Sarantopoulos J., et al. A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC). J Clin Oncol 25 18S (2007) 15601
65. Azad N.S., Posadas E.M., Kwitkowski V.E., et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. J Clin Oncol 24 18S (2006) 3004
66. Sosman J.A., Flaherty K., Atkins M.B., et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). J Clin Oncol 24 18S (2006) 3031
67. Tamaskar I., Garcia J.A., Elson P., et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179 1 (2008) 81-86 [discussion 86]
68. Rini B.I., George D.J., Michaelson M.D., et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol 24 18S (2006) 4522
69. Sablin M.P., Bouaita L., Balleyguier C., et al. Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. J Clin Oncol 25 18S (2007) 5038
70. Clark J.I., Atkins M.B., Urba W.J., et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomised trial. J Clin Oncol 21 16 (2003) 3133-3140
71. Messing E.M., Manola J., Wilding G., et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern cooperative oncology group/intergroup trial. J Clin Oncol 21 7 (2003) 1214-1222
72. Pizzocaro G., Piva L., Colavita M., et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomised study. J Clin Oncol 19 2 (2001) 425-431
73. Atzpodien J., Schmitt E., Gertenbach U., et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German cooperative renal carcinoma chemoimmunotherapy group (DGCIN). Brit J Cancer 92 5 (2005) 843-846
74. Rathmell KA, Amin,C. Wallen, E. Pruthi, R. Neoadjuvant therapy with sorafenib for locally advanced renal cell carcinoma (RCC). In: 2008 ASCO genitourinary cancers symposium [Abstract 370].